Clorox (NYSE:CLX) Earns “Neutral” Rating from DA Davidson

Clorox (NYSE:CLX)‘s stock had its “neutral” rating reiterated by equities research analysts at DA Davidson in a report issued on Wednesday, Benzinga reports. They currently have a $162.00 price objective on the stock. DA Davidson’s price target indicates a potential upside of 13.19% from the stock’s current price.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. boosted their price target on Clorox from $145.00 to $152.00 and gave the company a “neutral” rating in a report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft lowered their price target on Clorox from $155.00 to $151.00 and set a “hold” rating on the stock in a research report on Wednesday. The Goldman Sachs Group started coverage on Clorox in a research report on Friday, March 1st. They set a “sell” rating and a $140.00 price target on the stock. Citigroup lowered their price target on Clorox from $165.00 to $155.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Jefferies Financial Group raised Clorox from an “underperform” rating to a “hold” rating and set a $145.00 target price on the stock in a research report on Tuesday, March 26th. Four investment analysts have rated the stock with a sell rating and thirteen have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $148.63.

Clorox Stock Performance

CLX stock opened at $143.12 on Wednesday. The business’s 50-day moving average price is $150.18 and its two-hundred day moving average price is $141.70. The company has a current ratio of 0.89, a quick ratio of 0.57 and a debt-to-equity ratio of 11.37. The firm has a market cap of $17.76 billion, a PE ratio of 227.18, a P/E/G ratio of 2.22 and a beta of 0.43. Clorox has a 1-year low of $114.68 and a 1-year high of $178.21.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, February 1st. The company reported $2.16 earnings per share for the quarter, topping the consensus estimate of $1.08 by $1.08. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.80 billion. Clorox had a return on equity of 319.41% and a net margin of 1.09%. The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.98 earnings per share. As a group, research analysts forecast that Clorox will post 5.52 earnings per share for the current year.

Institutional Investors Weigh In On Clorox

Several institutional investors have recently made changes to their positions in the stock. Tyler Stone Wealth Management bought a new stake in Clorox during the second quarter worth $25,000. O Dell Group LLC bought a new stake in Clorox during the fourth quarter worth $28,000. Fortitude Family Office LLC bought a new stake in Clorox during the fourth quarter worth $29,000. Northwest Financial Advisors bought a new stake in Clorox during the fourth quarter worth $29,000. Finally, Core Wealth Advisors Inc. bought a new stake in Clorox during the fourth quarter worth $29,000. 78.53% of the stock is currently owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.